Liquidia Technologies, Inc. Stock

$13.10

2.10% yesterday

Nasdaq, Jun 27, 10:03 pm CET

ISIN

US53635D2027

Symbol

LQDA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Liquidia Technologies, Inc. Stock price

$13.10

+2.43 22.77% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.27 2.10%

ISIN

US53635D2027

Symbol

LQDA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$1.1b

Enterprise Value

$1.1b

Net debt

$-29.0m

Cash

$169.8m

Shares outstanding

85.3m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

79.20 | 28.04

EV/Sales

77.15 | 27.31

EV/FCF

negative

P/B

22.48

Financial Health

Equity Ratio

33.48%

Return on Equity

-169.34%

ROCE

-72.32%

ROIC

Debt/Equity

2.83

Financials (TTM | estimate)

Revenue

$14.1m | $39.9m

EBITDA

$-120.6m | $-105.5m

EBIT

$-120.7m

Net Income

$-127.8m | $-148.0m

Free Cash Flow

$-107.4m

Growth (TTM | estimate)

Revenue

-11.46% | 185.30%

EBITDA

-29.88% | 12.92%

EBIT

-29.85%

Net Income

-18.70% | -13.51%

Free Cash Flow

-54.50%

Margin (TTM | estimate)

Gross

58.08%

EBITDA

-852.76% | -264.26%

EBIT

-853.39%

Net

-903.80% | -370.53%

Free Cash Flow

-759.26%

EPS

$-1.50

FCF per Share

$-1.26

Short interest

28.41%

Employees

145.00

Rev per Employee

$100.00k

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Liquidia Technologies, Inc. Stock Analysis

Unlock Scores for Free

??

16 Analysts have issued a Liquidia Technologies, Inc. forecast:

14x Buy

88%

More details on Analyst Estimates Including Price Targets

16 Analysts have issued a Liquidia Technologies, Inc. forecast:

Buy

88%

Hold

Sell

Analyst Estimates with Stock Price Targets

Financial data from Liquidia Technologies, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	14 14	11% 11% 100%
- Direct Costs	5.93 5.93	60% 60% 42%
Gross Profit	8.22 8.22	33% 33% 58%
- Selling and Administrative Expenses	91 91	60% 60% 646%
- Research and Development Expense	45 45	7% 7% 316%
EBITDA	-121 -121	30% 30% -853%
- Depreciation and Amortization	0.09 0.09	13% 13% 1%
EBIT (Operating Income) EBIT	-121 -121	30% 30% -854%
Net Profit	-128 -128	19% 19% -904%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Liquidia Technologies, Inc. Stock News

Neutral

GlobeNewsWire

●

5 days ago

Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™

MORRISVILLE, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the receipt of an additional $50.0 million under its sixth amendment to its financing agreement (HCR Agreement) with Healthcare Royalty (HCRx) upon the U.S. District Court for the Mid...

Neutral

GlobeNewsWire

●

26 days ago

Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD

MORRISVILLE, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that Liquidia is scheduled to make its first commercial shipment of YUTREPIA™ (treprostinil) inhalation powder, marking the first time YUTREPIA will be available to be prescribed to p...

Neutral

GlobeNewsWire

●

about one month ago

Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference

MORRISVILLE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the company's Chief Executive Officer Dr. Roger Jeffs, Chief Financial Officer and Chief Operating Officer Michael Kaseta, and Chief Business Officer Jason Adair will be providing an update on the company's business during a fireside chat at the 2025 Jefferies Global Healthcare Conferenc...

More Liquidia Technologies, Inc. News

Company Profile

Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC.

Head office	United States
CEO	Roger Jeffs
Employees	145
Founded	2004
Website	www.liquidia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now